ATE389668T1 - Tumorantigen - Google Patents

Tumorantigen

Info

Publication number
ATE389668T1
ATE389668T1 AT01984425T AT01984425T ATE389668T1 AT E389668 T1 ATE389668 T1 AT E389668T1 AT 01984425 T AT01984425 T AT 01984425T AT 01984425 T AT01984425 T AT 01984425T AT E389668 T1 ATE389668 T1 AT E389668T1
Authority
AT
Austria
Prior art keywords
peptide
tumor antigen
polynucleotide
tumor antigens
tumor
Prior art date
Application number
AT01984425T
Other languages
English (en)
Inventor
Kyogo Itoh
Original Assignee
Greenpeptide Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greenpeptide Co Ltd filed Critical Greenpeptide Co Ltd
Application granted granted Critical
Publication of ATE389668T1 publication Critical patent/ATE389668T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01984425T 2000-07-31 2001-07-30 Tumorantigen ATE389668T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000231814 2000-07-31

Publications (1)

Publication Number Publication Date
ATE389668T1 true ATE389668T1 (de) 2008-04-15

Family

ID=18724591

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01984425T ATE389668T1 (de) 2000-07-31 2001-07-30 Tumorantigen

Country Status (9)

Country Link
US (6) US7148326B2 (de)
EP (1) EP1306431B1 (de)
JP (1) JP4900884B2 (de)
AT (1) ATE389668T1 (de)
AU (1) AU2002227498A1 (de)
CA (1) CA2417570C (de)
DE (1) DE60133287T2 (de)
ES (1) ES2304398T3 (de)
WO (1) WO2002010369A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476995A1 (en) * 2001-09-18 2003-03-27 Kyogo Itoh Method of detecting cellular immunity and application thereof to drugs
JP4721903B2 (ja) * 2004-01-29 2011-07-13 大日本住友製薬株式会社 新規腫瘍抗原蛋白質及びその利用
US20080200088A1 (en) * 2007-02-21 2008-08-21 Chong Pyung An Method for reducing interference fringes in a display device
KR101512885B1 (ko) 2007-09-18 2015-04-16 가부시키가이샤 그린 펩티드 Ｃｔｌ 유도제 조성물
EP2123748A1 (de) * 2008-05-20 2009-11-25 Institut Pasteur 2'-5'-Oligoadenylat-Synthetase 3 zur Vorbeugung und Behandlung von positivgerichteten einsträngigen RNA-Virusinfektionen
KR20120030383A (ko) 2009-04-22 2012-03-28 메르크 파텐트 게엠베하 변형된 ＦｃＲｎ 결합 자리를 갖는 항체 융합 단백질
RU2012103482A (ru) 2009-07-02 2013-08-10 АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ Способ лечения рака, основанный на использовании экзосом
EP2544005B1 (de) * 2010-03-03 2014-12-10 Toray Industries, Inc. Magenkrebsmarker und verfahren zur erkennung von magenkrebs
ES2791716T3 (es) 2010-12-14 2020-11-05 Univ Maryland Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer
US20140363825A1 (en) * 2011-08-29 2014-12-11 Kyoto University Marker for detecting colorectal cancer or esophageal cancer and method for examining such cancer
AU2013317194B2 (en) * 2012-09-11 2018-07-12 Oncotherapy Science, Inc. UBE2T peptides and vaccines containing the same
WO2014136814A1 (ja) 2013-03-08 2014-09-12 大鵬薬品工業株式会社 新規ｃｔｌエピトープ５連結ペプチド
KR101913333B1 (ko) 2013-10-21 2018-10-30 다이호야쿠힌고교 가부시키가이샤 신규 ctl 에피토프 4 연결 펩타이드
SG10202111399YA (en) 2015-12-22 2021-11-29 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
EP3579870A4 (de) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Auf car-t-zell-tumor (ctct) abzielende phospholipidether (ple)-wirkstoffe
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
EP3647433B1 (de) * 2017-06-30 2023-04-12 Osaka University Verfahren zur vorhersage der wirkung einer tumorimmunotherapie unter verwendung von tumorzytotoxischer aktivität von peripheren t-zellen im blut als index
JP7086980B2 (ja) 2017-10-26 2022-06-20 大塚製薬株式会社 イノシトールリン酸含有組成物
CA3089051A1 (en) 2018-01-22 2019-07-25 Endocyte, Inc. Methods of use for car t cells
MA53026A (fr) 2018-06-29 2021-05-05 Taiho Pharmaceutical Co Ltd Agent antitumoral et sa méthode d'évaluation
TW202135854A (zh) 2019-12-26 2021-10-01 日商大鵬藥品工業股份有限公司 術後輔助療法劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874231A (en) * 1994-08-22 1999-02-23 Mcgill University Methods of screening for non-hormone compounds which effect modulation of polypeptide translation
US5936078A (en) 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
AU1110297A (en) * 1995-12-12 1997-07-03 Kyowa Hakko Kogyo Co. Ltd. Novel dnas, novel polypeptides and novel antibodies
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
JP2000189168A (ja) * 1998-12-28 2000-07-11 Hiroshi Handa 新規転写伸長抑制因子
AU6321400A (en) * 1999-08-17 2001-03-13 Protegene Inc. Human proteins having hydrophobic domains and dnas encoding these proteins

Also Published As

Publication number Publication date
US7408037B2 (en) 2008-08-05
ES2304398T3 (es) 2008-10-16
JP4900884B2 (ja) 2012-03-21
US20070031433A1 (en) 2007-02-08
EP1306431B1 (de) 2008-03-19
EP1306431A4 (de) 2004-08-18
US20070071767A1 (en) 2007-03-29
CA2417570C (en) 2010-12-07
US20070066804A1 (en) 2007-03-22
US7432354B2 (en) 2008-10-07
US7404270B2 (en) 2008-07-29
US7524930B2 (en) 2009-04-28
US20070031431A1 (en) 2007-02-08
US20070031432A1 (en) 2007-02-08
US7427660B2 (en) 2008-09-23
EP1306431A1 (de) 2003-05-02
US7148326B2 (en) 2006-12-12
WO2002010369A1 (fr) 2002-02-07
AU2002227498A1 (en) 2002-02-13
US20030175288A1 (en) 2003-09-18
DE60133287T2 (de) 2009-03-26
DE60133287D1 (de) 2008-04-30
CA2417570A1 (en) 2003-01-31

Similar Documents

Publication Publication Date Title
ATE389668T1 (de) Tumorantigen
CY1105597T1 (el) Ανοσοθεραπευτικες μεθοδοι χρησιμοποιωντας επιτοπους των wt-1 και gata-1
FI950665A (fi) Melanoomaan liittyvä antigeeninen polypeptidi, sen epitooppeja ja melanoomarokotteita
PT2316940E (pt) Bibliotecas orientadas de pacotes genéticos
DE60142689D1 (de) Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
DE69910580D1 (de) Von der telomerase abgeleitete antigene peptide
WO2002074795A3 (en) Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
HUP9902438A2 (hu) Parapoxvírus vektorok
ATE464383T1 (de) Tumor antigen
DK1370284T3 (da) Bakteriofag-medieret immunisering
NO922421D0 (no) Collagenbindende protein, samt fremstilling derav
CY1105820T1 (el) Basb027 πρωτεϊνες και γονιδια απο moraxella catarrhalis, αντιγονα, αντισωματα και χρησεις
DE69928925D1 (de) Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
WO2002044202A3 (fr) Peptides immunogeniques mutes derives de r9m, polynucleotides les codant et leurs usages therapeutiques
ATE451461T1 (de) Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
WO1999057277A3 (en) Basb019 proteins and genes from moraxella catarrhalis, antigens, antibodies, and uses
WO2003008450A1 (fr) Antigenes tumoraux
ID27162A (id) Peptida antigen tumor yang dibatasi hla-a2 yang berasal dari sart-1
ATE397069T1 (de) Basb205 polypeptide und dafür kodierende polynukleotide
DE60140006D1 (de) Polypeptide aus haemophilus influenza
DE60019614D1 (de) Moraxella catarrhalis antigen basb117
DE60019613D1 (de) Moraxella catarrhalis antigen basb120
ATE311458T1 (de) Basb111 polypeptid und polynukleotid aus moraxella catharralis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties